Thomas K Karikari

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7861842/thomas-k-karikari-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

352	10,686	49	95
papers	citations	h-index	g-index
422 ext. papers	15,826 ext. citations	7.2 avg, IF	6.29 L-index

#	Paper	IF	Citations
352	Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults <i>Annals of Neurology</i> , 2022 ,	9.4	3
351	Amyloid processing in COVID-19 associated neurological syndromes <i>Journal of Neurochemistry</i> , 2022 ,	6	2
350	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease <i>EBioMedicine</i> , 2022 , 76, 103836	8.8	4
349	The accuracy and robustness of plasma biomarker models for amyloid PET positivity <i>Alzheimerh</i> s <i>Research and Therapy</i> , 2022 , 14, 26	9	4
348	Comparing tau status determined via plasma pTau181, pTau231 and [F]MK6240 tau-PET <i>EBioMedicine</i> , 2022 , 76, 103837	8.8	1
347	A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease <i>Alzheimerl</i> s and Dementia: Translational Research and Clinical Interventions, 2022 , 8, e12270	6	
346	Neurological signs of ageing 2022 , 561-569		
345	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design <i>Alzheimerh</i> and <i>Dementia</i> , 2022 ,	1.2	3
344	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change <i>Acta Neuropathologica</i> , 2022 , 143, 487	14.3	6
343	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for -associated frontotemporal dementia and amyotrophic lateral sclerosis <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 ,	5.5	2
342	New insights into the genetic etiology of Alzheimer's disease and related dementias <i>Nature Genetics</i> , 2022 ,	36.3	27
341	Familial British dementia: a clinical and multi-modal imaging case study Journal of Neurology, 2022, 1	5.5	
340	Effect of Race on Prediction of Brain Amyloidosis by Plasma A型2/A型0, Phosphorylated Tau, and Neurofilament Ligh <i>Neurology</i> , 2022 ,	6.5	4
339	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients <i>Dementia and Geriatric Cognitive Disorders</i> , 2022 , 1-11	2.6	0
338	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease <i>Alzheimerl</i> s <i>Research and Therapy</i> , 2022 , 14, 65	9	2
337	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility <i>Nature Reviews Neurology</i> , 2022 ,	15	4
336	latrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon <i>Journal of Neurology,</i> Neurosurgery and Psychiatry, 2022 ,	5.5	1

Population-based blood screening for pre-clinical Alzheimer disease: a British birth cohort at age 70. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A91.2-A91	5.5	
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021 , 78, 1471-1483	17.2	18
Truncating tau reveals different pathophysiological actions of oligomers in single neurons. <i>Communications Biology</i> , 2021 , 4, 1265	6.7	О
Loss and dispersion of superficial white matter in Alzheimer's disease: a diffusion MRI study. <i>Brain Communications</i> , 2021 , 3, fcab272	4.5	1
Prodromal frontotemporal dementia: clinical features and predictors of progression. <i>Alzheimerl</i> s <i>Research and Therapy</i> , 2021 , 13, 188	9	О
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2021 ,	17.2	4
The global Alzheimer's Association round robin study on plasma amyloid [methods. <i>Alzheimerls and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12242	5.2	2
Dissociable effects of -A and Amyloid pathology on visual working memory. <i>Nature Aging</i> , 2021 , 1, 1002-1009		2
P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021 , 13, e15098	12	4
Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. <i>Brain</i> , 2021 , 144, 434-449	11.2	21
A population-based study of head injury, cognitive function and pathological markers. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 842-856	5.3	1
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2140-2156	8.8	31
Extract Depresses Excitatory Synaptic Transmission and Chemically-Induced Seizures in the Rat Hippocampus. <i>Frontiers in Pharmacology</i> , 2021 , 12, 610025	5.6	1
New insights into atypical Alzheimer's disease in the era of biomarkers. <i>Lancet Neurology, The</i> , 2021 , 20, 222-234	24.1	45
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. <i>Alzheimerh Research and Therapy</i> , 2021 , 13, 65	9	13
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimerh Research and Therapy</i> , 2021 , 13, 69	9	10
Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. <i>Molecular Psychiatry</i> , 2021 ,	15.1	10
Investigating the relationship between BMI across adulthood and late life brain pathologies. Alzheimerls Research and Therapy, 2021, 13, 91	9	O
	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Communications Biology, 2021, 4, 1265 Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Communications Biology, 2021, 4, 1265 Loss and dispersion of superficial white matter in Alzheimer's disease: a diffusion MRI study. Brain Communications, 2021, 3, fcab272 Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimerls Research and Therapy, 2021, 13, 188 Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2021, The global Alzheimer's Association round robin study on plasma amyloid Inethods. Alzheimerls and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12242 Dissociable effects of -B and Bamyloid pathology on visual working memory. Nature Aging, 2021, 1, 1002-1009 P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. EMBO Molecular Medicine, 2021, 13, e15098 Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain, 2021, 144, 434-449 A population-based study of head injury, cognitive function and pathological markers. Annals of Clinical and Translational Neurology, 2021, 8, 842-856 The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers of amyloid and phosphoryal and Linical disease progression. Alzheimer's Resea	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471-1483 17-2 Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Communications Biology, 2021, 4, 1265 Loss and dispersion of superficial white matter in Alzheimer's disease: a diffusion MRI study. Brain Communications, 2021, 3, feab272 Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research and Therapy, 2021, 13, 188 Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2021, The global Alzheimer's Association round robin study on plasma amyloid finethods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12242 Dissociable effects of -8 and Bamyloid pathology on visual working memory. Nature Agling, 2021, 1, 1022-1099 P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. EMBO Molecular Medicine, 2021, 13, e15098 A population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain, 2021, 144, 434-449 A population-based study of head injury, cognitive function and pathological markers. Annals of Clinical and Translational Neurology, 2021, 8, 842-856 The validation status of blood biomarkers of amyloid and phospho-tau assessed with the S-phase development framework for AD biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2140-2156 Extract Depresses Excitatory Synaptic Transmission and Chemically-Induced Seizures in the Rat Hippocampus. Frontiers in Pharmacology, 2021, 12, 610025 New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurology, The, 2021, 20, 222-234 Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. Alzheimerhs

317	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021 , 3, fcab073	4.5	7
316	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021 , 78, 396-406	17.2	41
315	Beyond the average patient: how neuroimaging models can address heterogeneity in dementia. <i>Brain</i> , 2021 , 144, 2946-2953	11.2	10
314	KL*VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE*4 carriers. <i>Neurobiology of Aging</i> , 2021 , 101, 123-129	5.6	4
313	Subjective cognitive complaints at age 70: associations with amyloid and mental health. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1215-1221	5.5	2
312	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1206-1214	5.5	10
311	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021 , 290, 583-601	10.8	15
310	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51
309	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021 , 3, fcab136	4.5	3
308	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. <i>Movement Disorders</i> , 2021 , 36, 632-641	7	2
308 307		7	4
	Movement Disorders, 2021 , 36, 632-641		
307	Movement Disorders, 2021, 36, 632-641 Genetic testing in dementia - utility and clinical strategies. Nature Reviews Neurology, 2021, 17, 23-36 Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers	15	4
3°7 3°6	Movement Disorders, 2021, 36, 632-641 Genetic testing in dementia - utility and clinical strategies. Nature Reviews Neurology, 2021, 17, 23-36 Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimerls and Dementia, 2021, 17, 755-767 Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain,	1.2	4 31
307 306 305	Movement Disorders, 2021, 36, 632-641 Genetic testing in dementia - utility and clinical strategies. Nature Reviews Neurology, 2021, 17, 23-36 Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimerls and Dementia, 2021, 17, 755-767 Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain, 2021, 144, 325-339	15 1.2 11.2	4 31 42
307 306 305 304	Genetic testing in dementia - utility and clinical strategies. <i>Nature Reviews Neurology</i> , 2021 , 17, 23-36 Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimerls and Dementia</i> , 2021 , 17, 755-767 Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021 , 144, 325-339 Mild cognitive impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021 , 50, 72-80 Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the	15 1.2 11.2 3	4 31 42 20
307 306 305 304 303	Genetic testing in dementia - utility and clinical strategies. <i>Nature Reviews Neurology</i> , 2021 , 17, 23-36 Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimerls and Dementia</i> , 2021 , 17, 755-767 Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021 , 144, 325-339 Mild cognitive impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021 , 50, 72-80 Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021 , 26, 429-442 Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimerls and Dementia: Diagnosis, Assessment and Disease</i>	15 1.2 11.2 3	4 31 42 20 70

(2021-2021)

299	concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. <i>Alzheimerh</i> and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021 , 13, e12131	5.2	O	
298	Investigating the Relationship Between IGF-I, IGF-II, and IGFBP-3 Concentrations and Later-Life Cognition and Brain Volume. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1617-1629	5.6	2	
297	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021 , 141, 709-724	14.3	83	
296	Plasma P-tau181 to A½2 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimerl</i> s and Dementia, 2021, 17, 1649-1662	1.2	12	
295	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021 ,	6.5	5	
294	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021 , 12, 4304	17.4	11	
293	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. <i>Journal of Neurology</i> , 2021 , 1	5.5	2	
292	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021 , 27, 1592-15	93 0.5	44	
291	Aducanumab: a new phase in therapeutic development for Alzheimer's disease?. <i>EMBO Molecular Medicine</i> , 2021 , 13, e14781	12	19	
290	Reply: Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2021 , 144, e73	11.2	1	
289	Grip strength from midlife as an indicator of later-life brain health and cognition: evidence from a British birth cohort. <i>BMC Geriatrics</i> , 2021 , 21, 475	4.1	2	
288	Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations. <i>Movement Disorders</i> , 2021 , 36, 2481-2493	7	O	
287	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021 , 78, 1108-1117	17.2	25	
286	Sex-related differences in whole brain volumes at age 70 in association with hyperglycemia during adult life <i>Neurobiology of Aging</i> , 2021 , 112, 161-169	5.6	О	
285	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimerl</i> s and <i>Dementia</i> , 2021 ,	1.2	11	
284	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery</i>	5.5	14	
	and Psychiatry, 2021 , 92, 1231-1241			
283	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021 , 106, 304.e1-304.e3	5.6	1	

281	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimerl</i> s and Dementia, 2021 , 17, 1145-1156	1.2	48
2 80	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021 , 3, fcab099	4.5	15
279	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview <i>Alzheimerl</i> s and Dementia, 2021,	1.2	3
278	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimerl</i> s and Dementia, 2021 , 17,	1.2	1
277	The heterogeneous brain: Mapping individualised patterns of atrophy in Alzheimer disease using spatial normative models. <i>Alzheimer</i> and <i>Dementia</i> , 2021 , 17,	1.2	1
276	Plasma phospho-tau181 in over 400 cognitively healthy 69- to 71-year-olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. <i>Alzheimerl</i> s and Dementia, 2020, 16, e037848	1.2	
275	Vascular risk factors and amyloid pathology: Additive or interactive associations?. <i>Alzheimerl</i> s and <i>Dementia</i> , 2020 , 16, e037922	1.2	
274	The differential genetic architecture between posterior cortical atrophy and amnestic Alzheimer's disease. <i>Alzheimerl</i> s and Dementia, 2020 , 16, e038851	1.2	O
273	Alzheimer disease biomarker roadmap 2020: Fluid biomarkers. <i>Alzheimerh and Dementia</i> , 2020 , 16, e039557	1.2	0
272	Uncovering superficial white matter changes in young-onset Alzheimer disease. <i>Alzheimer and Dementia</i> , 2020 , 16, e039746	1.2	
271	Performance on the graded naming test in a population-based sample of 72-year-olds: Associations with life-course predictors and Eamyloid pathology. <i>Alzheimerl</i> s and Dementia, 2020 , 16, e040897	1.2	
270	Accelerated forgetting is sensitive to Emyloid pathology and cerebral atrophy in cognitively normal 72-year-olds. <i>Alzheimerh and Dementia</i> , 2020 , 16, e040987	1.2	
269	APOE-A carriers have superior recall on the What was where? I visual short-term memory binding test at age 70, despite a detrimental effect of Emyloid. <i>Alzheimerh and Dementia</i> , 2020 , 16, e041090	1.2	2
268	Lifetime cigarette smoking and later-life brain health: The population-based 1946 British Birth Cohort. <i>Alzheimerl</i> s and Dementia, 2020 , 16, e041111	1.2	
267	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer disease in the absence of AT(N) classification as the reference standard. <i>Alzheimer</i> and <i>Dementia</i> , 2020 , 16, e041	8 0 8	0
266	Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology. <i>Alzheimerh</i> and Dementia, 2020 , 16, e041849	1.2	O
265	Plasma phospho-tau in familial Alzheimer disease. Alzheimer and Dementia, 2020, 16, e042921	1.2	
264	Cerebral amyloid and white matter hyperintensity volume are independently associated with rates of cerebral atrophy in Insight 46, a sub-study of the 1946 British birth cohort. <i>Alzheimerl</i> s and <i>Dementia</i> , 2020 , 16, e044924	1.2	

(2020-2020)

263	CSF phosphorylated tau-217 is increased in Alzheimer and Creutzfeldt-Jakob diseases and correlates with amyloid pathology. <i>Alzheimer and Dementia</i> , 2020 , 16, e045296	1.2	3
262	Augmenting cognitive assessment with instruction-less Eye-tracking tests: A machine learning approach for detecting abnormal oculomotor biomarkers. <i>Alzheimerh</i> and Dementia, 2020, 16, e045318	1.2	
261	An extensive plasmid library for preparing tau variants and studying their functional biochemistry. <i>Alzheimerl</i> s and <i>Dementia</i> , 2020 , 16, e045387	1.2	
260	Augmenting cognitive assessment with instruction-less eye-tracking tests: A machine learning approach for detecting abnormal oculomotor biomarkers. <i>Alzheimerh</i> and Dementia, 2020 , 16, e045483	1.2	
259	Mid-life blood pressure and microstructural white matter: Findings from the 1946 British birth cohort. <i>Alzheimerh</i> and Dementia, 2020 , 16, e045707	1.2	
258	Multimodal modelling of the heterogeneity of Alzheimer disease. <i>Alzheimer and Dementia</i> , 2020 , 16, e045822	1.2	1
257	Serum neurofilament light and whole brain volume associate with machine-learning derived brain-predicted age in the British 1946 birth cohort. <i>Alzheimerh</i> and Dementia, 2020 , 16, e045965	1.2	1
256	Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET. <i>Alzheimerh</i> and Dementia, 2020 , 16, e045991	1.2	
255	Plasma-based biomarkers for Aland tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer disease. <i>Alzheimer and Dementia</i> , 2020 , 16, e046490	1.2	
254	Plasma p-tau181 accurately predicts Alzheimer disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer and Dementia</i> , 2020 , 16, e047539	1.2	2
253	How to diagnose difficult white matter disorders. <i>Practical Neurology</i> , 2020 , 20, 280-286	2.4	
252	Diagnostic and prognostic value of serum NfL and p-Tau in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020 , 91, 960-967	5.5	51
251	The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. <i>Brain</i> , 2020 , 143, 3104-3120	11.2	543
250	Olfactory testing does not predict Emyloid, MRI measures of neurodegeneration or vascular pathology in the British 1946 birth cohort. <i>Journal of Neurology</i> , 2020 , 267, 3329-3336	5.5	1
249	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimerl</i> s <i>Research and Therapy</i> , 2020 , 12, 20	9	13
248	Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020 , 49, 56-76	2.6	7
247	Pure tone audiometry and cerebral pathology in healthy older adults. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 172-176	5.5	7
246	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020 , 35, 601-611	12.1	23

245	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. <i>Brain Stimulation</i> , 2020 , 13, 1031-1039	5.1	15
244	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimerl</i> s <i>Disease</i> , 2020 , 74, 1189-1201	4.3	19
243	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020 , 16, 265-284	15	53
242	Study Protocol - Insight 46 Cardiovascular: A Sub-study of the MRC National Survey of Health and Development. <i>Artery Research</i> , 2020 , 26, 170-179	2.2	1
241	Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease. <i>Alzheimerh</i> and Dementia, 2020 , 16, e043060	1.2	
240	A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond. <i>Brain Communications</i> , 2020 , 2, fcz047	4.5	18
239	Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life: Evidence From a British Birth Cohort. <i>JAMA Neurology</i> , 2020 , 77, 175-183	17.2	21
238	Diet quality in late midlife is associated with faster walking speed in later life in women, but not men: findings from a prospective British birth cohort. <i>British Journal of Nutrition</i> , 2020 , 123, 913-921	3.6	2
237	Understanding the Pathophysiological Actions of Tau Oligomers: A Critical Review of Current Electrophysiological Approaches. <i>Frontiers in Molecular Neuroscience</i> , 2020 , 13, 155	6.1	10
236	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2020 ,	15.1	36
235	A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis. <i>Nature Communications</i> , 2020 , 11, 3960	17.4	8
234	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020 , 140, 267-278	14.3	79
233	Increased variability in reaction time is associated with amyloid beta pathology at age 70. <i>Alzheimerh</i> and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020 , 12, e12076	5.2	4
232	Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2020 , 143, 2895-2903	11.2	27
231	Diffuse axonal injury predicts neurodegeneration after moderate-severe traumatic brain injury. <i>Brain</i> , 2020 , 143, 3685-3698	11.2	13
230	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. <i>Alzheimerl</i> s Research and Therapy, 2020 , 12, 112	9	7
229	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimerh</i> Disease, 2020 , 77, 1129-1141	4.3	25
228	Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 3117-3129	5.7	4

227	Altered DNA methylation profiles in blood from patients with sporadic Creutzfeldt-Jakob disease. <i>Acta Neuropathologica</i> , 2020 , 140, 863-879	14.3	3
226	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Alþathology are detected. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12921	12	67
225	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. <i>Molecular Psychiatry</i> , 2020 , 25, 2919-2931	15.1	51
224	Construction and reconstruction of brain circuits: normal and pathological axon guidance. <i>Journal of Neurochemistry</i> , 2020 , 153, 10-32	6	11
223	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology, The</i> , 2020 , 19, 422-433	24.1	286
222	The C291R Tau Variant Forms Different Types of Protofibrils. <i>Frontiers in Molecular Neuroscience</i> , 2020 , 13, 39	6.1	7
221	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. <i>Alzheimerh</i> and Dementia: Translational Research and Clinical Interventions, 2019 , 5, 382-387	6	17
220	Looking beyond the eyes: visual impairment in posterior cortical atrophy. <i>Lancet, The</i> , 2019 , 394, 1055	40	1
219	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 1035-1048	17.2	237
218	SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2019 , 15, 419-427	15	22
217	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. <i>Brain</i> , 2019 , 142, 2082-2095	11.2	36
216	Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery. <i>Scientific Reports</i> , 2019 , 9, 4191	4.9	7
215	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 740-746	5.5	14
214	ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-Itopathology. <i>Alzheimerh and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 277-280	5.2	16
213	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. <i>Alzheimerl</i> s <i>Research and Therapy</i> , 2019 , 11, 19	9	47
212	Biomarkers for Alzheimer's disease beyond amyloid and tau. <i>Nature Medicine</i> , 2019 , 25, 201-203	50.5	24
211	The functional neuroanatomy of musical memory in Alzheimer's disease. <i>Cortex</i> , 2019 , 115, 357-370	3.8	11
2 10	Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. <i>Lancet Neurology, The</i> , 2019 , 18, 942-952	24.1	95

209	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease <i>Clinical Mass Spectrometry</i> , 2019 , 14 Pt B, 74-82	1.9	1
208	Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. <i>Alzheimerl</i> s <i>Research and Therapy</i> , 2019 , 11, 62	9	23
207	Distinct Conformations, Aggregation and Cellular Internalization of Different Tau Strains. <i>Frontiers in Cellular Neuroscience</i> , 2019 , 13, 296	6.1	25
206	Hippocampal subfield volumes and pre-clinical Alzheimer's disease in 408 cognitively normal adults born in 1946. <i>PLoS ONE</i> , 2019 , 14, e0224030	3.7	13
205	Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process. <i>NeuroImage: Clinical</i> , 2019 , 24, 102051	5.3	2
204	Cognition at age 70: Life course predictors and associations with brain pathologies. <i>Neurology</i> , 2019 , 93, e2144-e2156	6.5	17
203	Introduction of Tau Oligomers into Cortical Neurons Alters Action Potential Dynamics and Disrupts Synaptic Transmission and Plasticity. <i>ENeuro</i> , 2019 , 6,	3.9	25
202	Differences in topological progression profile among neurodegenerative diseases from imaging data. <i>ELife</i> , 2019 , 8,	8.9	8
201	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Alltau, immunity and lipid processing. <i>Nature Genetics</i> , 2019 , 51, 414-430	36.3	917
200	IC-P-007: CENTILOID SCALE TRANSFORMATION OF FLORBETAPIR DATA ACQUIRED ON A PET/MR SCANNER 2019 , 15, P17-P18		
199	CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. <i>Alzheimerhs Research and Therapy</i> , 2019 , 11, 105	9	17
198	P4-490: ALZHEIMER'S DISEASE POLYGENIC BURDEN BEYOND APOE ACTS STRONGER ON TAU THAN ON AMYLOID 2019 , 15, P1500-P1501		
197	O4-13-01: EARLY ADULTHOOD VASCULAR RISK STRONGLY PREDICTS BRAIN VOLUMES AND WHITE MATTER DISEASE, BUT NOT AMYLOID STATUS, AT AGE 69½1 YEARS: EVIDENCE FROM A BRITISH BIRTH COHORT 2019 , 15, P1269-P1270		
196	Incidental findings on brain imaging and blood tests: results from the first phase of Insight 46, a prospective observational substudy of the 1946 British birth cohort. <i>BMJ Open</i> , 2019 , 9, e029502	3	7
195	IC-P-006: LONGITUDINAL RATES OF AMYLOID ACCUMULATION IN A 70-YEAR OLD BRITISH BIRTH COHORT 2019 , 15, P16-P17		
194	Sleep symptoms in syndromes of frontotemporal dementia and Alzheimer's disease: A proof-of-principle behavioural study. <i>ENeurologicalSci</i> , 2019 , 17, 100212	2.1	6
193	Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL-MRI: proof of concept. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 2419-2432	7.3	7
192	Differences in hippocampal subfield volume are seen in phenotypic variants of early onset Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019 , 21, 101632	5.3	22

191	Unsuccessful trials of therapies for Alzheimer's disease. Lancet, The, 2019, 393, 29	40	18
190	Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. <i>Alzheimerh and Dementia</i> , 2019 , 15, 487-496	1.2	60
189	Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 543-554	5.5	37
188	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimerl</i> s and <i>Dementia</i> , 2019 , 15, 388-399	1.2	19
187	Preparation of stable tau oligomers for cellular and biochemical studies. <i>Analytical Biochemistry</i> , 2019 , 566, 67-74	3.1	20
186	CSF Beta-amyloid 1-42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. <i>Annals of Surgery</i> , 2019 , 269, 1200-1205	7.8	24
185	Hippocampal subfield volumes and pre-clinical Alzheimer∃ disease in 408 cognitively normal adults born in 1946 2019 , 14, e0224030		
184	Hippocampal subfield volumes and pre-clinical Alzheimer disease in 408 cognitively normal adults born in 1946 2019 , 14, e0224030		
183	Hippocampal subfield volumes and pre-clinical Alzheimer disease in 408 cognitively normal adults born in 1946 2019 , 14, e0224030		
182	Hippocampal subfield volumes and pre-clinical Alzheimer disease in 408 cognitively normal adults born in 1946 2019 , 14, e0224030		
181	Susceptibility of brain atrophy to in Alzheimer's disease, evidence from functional prioritization in imaging genetics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 3162-3167	11.5	25
180	Cortical microstructure in young onset Alzheimer's disease using neurite orientation dispersion and density imaging. <i>Human Brain Mapping</i> , 2018 , 39, 3005-3017	5.9	55
179	Primary progressive aphasia: a clinical approach. <i>Journal of Neurology</i> , 2018 , 265, 1474-1490	5.5	101
178	Plasma tau is increased in frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 804-807	5.5	28
177	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology, The</i> , 2018 , 17, 123-132	24.1	47
176	Motor signatures of emotional reactivity in frontotemporal dementia. <i>Scientific Reports</i> , 2018 , 8, 1030	4.9	21
175	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 162-171	5.3	23
174	Amyloid [peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. <i>Alzheimerls and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 311-321	5.2	15

173	Data-driven models of dominantly-inherited Alzheimer's disease progression. <i>Brain</i> , 2018 , 141, 1529-1	54A1.2	66
172	Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimerh</i> and <i>Dementia</i> , 2018 , 14, 895-901	1.2	6
171	Clinicopathological case: progressive somnolence and dementia in an accountant: when the shine rubs off the gold standard. <i>Practical Neurology</i> , 2018 , 18, 505-512	2.4	
170	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018 , 360,	33.3	666
169	Commentary: Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Frontiers in Neurology</i> , 2018 , 9, 201	4.1	21
168	Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. <i>Alzheimerl</i> s and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 448-451	5.2	35
167	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimerh Research and Therapy</i> , 2018 , 10, 32	9	57
166	Molecular biomarkers of Alzheimer's disease: progress and prospects. <i>DMM Disease Models and Mechanisms</i> , 2018 , 11,	4.1	109
165	An extract of Synedrella nodiflora (L) Gaertn exhibits antidepressant properties through monoaminergic mechanisms. <i>Metabolic Brain Disease</i> , 2018 , 33, 1359-1368	3.9	3
164	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimerl</i> Research and Therapy, 2018 , 10, 79	9	31
163	Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci. <i>Brain</i> , 2018 , 141, 2167-2180	11.2	34
162	Kenya and Ghana set up national research funding schemes. <i>Nature</i> , 2018 , 557, 166	50.4	2
161	IC-P-151: AN EVENT-BASED MODEL OF ALZHEIMER'S DISEASE IN APOE+ SUBJECTS USING ROBUST BIOMARKERS OF VOLUMETRIC CHANGE IN REGIONAL BRAIN STRUCTURE 2018 , 14, P129-P129		
160	P3-196: DISTINCT CONFORMATIONS, AGGREGATION AND NEURONAL PROPAGATION OF DIFFERENT TAU STRAINS 2018 , 14, P1142-P1142		
159	P1-267: CEREBROSPINAL FLUID/PLASMA ALBUMIN RATIO PREDICTS POSTOPERATIVE DELIRIUM IN AN OLDER ELECTIVE ORTHOPAEDIC POPULATION 2018 , 14, P384-P384		
158	P3-420: AN EVENT BASED MODEL OF ALZHEIMER'S DISEASE IN APOE+ SUBJECTS USING ROBUST BIOMARKERS OF VOLUMETRIC CHANGE IN REGIONAL BRAIN STRUCTURE 2018 , 14, P1268-P1269		
157	P1-188: MODELLING AMYLOID BETA PROFILES IN IPSC-DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE 2018 , 14, P350-P351		
156	O2-04-04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE 2018 , 14, P623-P624		

155	ONSET ALZHEIMER'S DISEASE 2018 , 14, P850-P851		
154	O3-14-04: THE PROTEIN-TO-PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULE-ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER 2018 , 14, P1060-P1	061	
153	P3-437: LONGITUDINAL CORTICAL THICKNESS IN SPORADIC YOUNG ONSET ALZHEIMER'S DISEASE 2018 , 14, P1281-P1281		
152	IC-P-076: GENOMEWIDE ASSOCIATION STUDY OF DATA-DRIVEN ALZHEIMER'S DISEASE SUBTYPES 2018 , 14, P67-P68		
151	O3-10-04: GENOMEWIDE ASSOCIATION STUDY OF DATA-DRIVEN ALZHEIMER'S DISEASE SUBTYPES 2018 , 14, P1042-P1043		1
150	P1-474: SURFACE-BASED ANALYSIS OF CORTICAL GREY MATTER MICROSTRUCTURE IN YOUNG-ONSET ALZHEIMER'S DISEASE USING NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING (NODDI) 2018 , 14, P505-P505		
149	Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46. <i>BMC Research Notes</i> , 2018 , 11, 885	2.3	25
148	Medicinal Plants Used in the Treatment of Mental and Neurological Disorders in Ghana. Evidence-based Complementary and Alternative Medicine, 2018 , 2018, 8590381	2.3	12
147	O2-05-01: INFLUENCES OF BLOOD PRESSURE AND BLOOD PRESSURE TRAJECTORIES ON CEREBRAL PATHOLOGY AT AGE 70: RESULTS FROM A BRITISH BIRTH COHORT 2018 , 14, P626-P627		1
146	P3-261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE 2018 , 14, P1174-P1175		
145	P1-301: CERTAIN PLASMA N-TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND AD-MCI COMPARED TO CONTROLS 2018 , 14, P405-P405		
144	P1-031: HEAD INJURY WITH LOSS OF CONSCIOUSNESS AND SUBSEQUENT COGNITIVE DECLINE: FOLLOW-UP IN THE 1946 BRITISH BIRTH COHORT STUDY 2018 , 14, P278-P279		1
143	Prevalence of amyloid-pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018 , 84, 729-740	9.4	74
142	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. <i>Nature Communications</i> , 2018 , 9, 4273	17.4	125
141	Navigating Genetic Influences on the Topography of Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018 , 84, 476-477	7.9	
140	Redefining the phenotype of ALSP and mutation-related leukodystrophy. <i>Neurology: Genetics</i> , 2017 , 3, e135	3.8	49
139	Consensus classification of posterior cortical atrophy. <i>Alzheimerl</i> s and Dementia, 2017, 13, 870-884	1.2	261
138	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 908-916	5.5	45

137	Imaging the ageing brain: identifying early disease or opening Pandora's box?. <i>Lancet Neurology, The</i> , 2017 , 16, 411-413	24.1	2
136	ApoE influences regional white-matter axonal density loss in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 57, 8-17	5.6	49
135	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 767-775	4.3	4
134	Clinical and genetic characterization of leukoencephalopathies in adults. <i>Brain</i> , 2017 , 140, 1204-1211	11.2	51
133	Cognitive decline before diagnosis of Parkinson's disease - Authors' reply. <i>Lancet Neurology, The</i> , 2017 , 16, 262	24.1	2
132	A Comparison of Accelerated and Non-accelerated MRI Scans for Brain Volume and Boundary Shift Integral Measures of Volume Change: Evidence from the ADNI Dataset. <i>Neuroinformatics</i> , 2017 , 15, 215	- 22 6	10
131	Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. <i>Neurology</i> , 2017 , 89, 2167-2175	6.5	154
130	A Model Approach to Public Engagement Training for Students in Developing Countries. <i>Journal of Microbiology and Biology Education</i> , 2017 , 18,	1.3	1
129	Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis. <i>BMC Complementary and Alternative Medicine</i> , 2017 , 17, 389	4.7	10
128	Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. <i>F1000Research</i> , 2017 , 6, 1604	3.6	23
127	An ethanolic extract of Desmodium adscendens exhibits antipsychotic-like activity in mice. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2017 , 28, 507-518	1.6	2
126	[IC-P-004]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER 2017 , 13, P12-P13		
125	Inhibiting the Ca Influx Induced by Human CSF. Cell Reports, 2017, 21, 3310-3316	10.6	14
124	[P4\(\bar{D}\)61]: LONGITUDINAL EVALUATION OF NEUROPSYCHOLOGICAL AND NEUROIMAGING PROGRESSION IN POSTERIOR CORTICAL ATROPHY 2017 , 13, P1382-P1383		
123	[P1월43]: MULTIPLE DISTINCT ATROPHY PATTERNS FOUND IN GENETIC FRONTOTEMPORAL DEMENTIA USING SUBTYPE AND STAGE INFERENCE (SUSTAIN) 2017 , 13, P453-P454		1
122	[IC-P-079]: MULTIPLE DISTINCT ATROPHY PATTERNS FOUND IN GENETIC FRONTOTEMPORAL DEMENTIA USING SUBTYPE AND STAGE INFERENCE (SUSTAIN) 2017 , 13, P65-P66		
121	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , 2017 , 16, 661-676	24.1	308
120	Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development. <i>BMC Neurology</i> , 2017 , 17, 75	3.1	42

119	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. <i>Molecular Diagnosis and Therapy</i> , 2017 , 21, 13-22	4.5	26
118	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <i>Lancet Neurology, The</i> , 2017 , 16, 66-75	24.1	201
117	Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag. <i>Protein Expression and Purification</i> , 2017 , 130, 44-54	2	20
116	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-Concentration. <i>Journal of Alzheimerl</i> Disease, 2017 , 56, 885-891	4.3	5
115	[P2월14]: CHARACTERISING THE PROGRESSION OF ALZHEIMER'S DISEASE SUBTYPES USING SUBTYPE AND STAGE INFERENCE (SUSTAIN) 2017 , 13, P791-P792		
114	[P2B45]: VASCULAR AND EARLY LIFE INFLUENCES ON CEREBROVASCULAR DISEASE IN INSIGHT 46: A SUB-STUDY OF THE MRC NATIONAL SURVEY OF HEALTH AND DEVELOPMENT (NSHD) BRITISH BIRTH COHORT 2017 , 13, P851-P853		
113	[P3B48]: EXPLORING THE POPULATION PREVALENCE OF FAMYLOID BURDEN: AN ANALYSIS OF 250 INDIVIDUALS BORN IN MAINLAND BRITAIN IN THE SAME WEEK IN 1946 2017 , 13, P1088-P1089		
112	[P3B73]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER 2017 , 13, P1100-P1101		
111	[P4230]: LONGITUDINAL NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING IN YOUNG-ONSET ALZHEIMER'S DISEASE 2017 , 13, P1359-P1360		
110	[IC-P-047]: THE ROLE OF HIPPOCAMPAL SUBFIELDS IN THE ATROPHY PROCESS IN ALZHEIMER'S DISEASE: AN IN-VIVO STUDY OF THE ADNI COHORT 2017 , 13, P40-P41		1
109	[IC-P-154]: CHARACTERISING THE PROGRESSION OF ALZHEIMER's DISEASE SUBTYPES USING SUBTYPE AND STAGE INFERENCE (SUSTAIN) 2017 , 13, P116-P117		1
108	[IC-P-168]: LONGITUDINAL NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING IN YOUNG-ONSET ALZHEIMER'S DISEASE 2017 , 13, P127-P127		
107	[P1B35]: THEMES AND VARIATIONS IN PPA: A CLINICAL AND NEUROBIOLOGICAL ANALYSIS OF THE UCL COHORT 2017 , 13, P384-P385		
106	[P1B48]: CSF AB2 CONCENTRATION INDEPENDENTLY PREDICTS POSTOPERATIVE DELIRIUM IN AN ELDERLY ELECTIVE ARTHROPLASTY POPULATION 2017 , 13, P390-P390		
105	[P1월65]: PROGRESSIVE CALLOSAL ATROPHY WITH STABLE MEMORY IMPAIRMENT IN FAMILIAL BRITISH DEMENTIA 2017 , 13, P465-P467		
104	[P2Ø41]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER's DISEASE 2017 , 13, P703-P704		
103	[O1003]: BIOMARKERS OF INFLAMMATION IN ALZHEIMER's DISEASE 2017, 13, P215		1
102	[O40204]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY 2017 , 13, P1230-P1231		

[O5\overline{0}5\overline{0}4]: BRAIN VOLUME, CEREBRAL \overline{0}AMYLOID DEPOSITION, AND AGEING: A STUDY OF OVER 200 INDIVIDUALS BORN IN THE SAME WEEK IN 1946 **2017**, 13, P1464-P1465

100	Eyetracking Metrics in Young Onset Alzheimer's Disease: A Window into Cognitive Visual Functions. <i>Frontiers in Neurology</i> , 2017 , 8, 377	4.1	29
99	Data-Driven Sequence of Changes to Anatomical Brain Connectivity in Sporadic Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2017 , 8, 580	4.1	29
98	[P2월09]: THE ROLE OF HIPPOCAMPAL SUBFIELDS IN THE ATROPHY PROCESS IN ALZHEIMER'S DISEASE: AN IN-VIVO STUDY OF THE ADNI COHORT. <i>Alzheimerh</i> and Dementia, 2017 , 13, P788	1.2	1
97	Music Perception in Dementia. <i>Journal of Alzheimerh</i> Disease, 2017 , 55, 933-949	4.3	24
96	Cerebrospinal fluid in the dementias. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2017 , 146, 85-97	3	9
95	Building sustainable neuroscience capacity in Africa: the role of non-profit organisations. <i>Metabolic Brain Disease</i> , 2016 , 31, 3-9	3.9	22
94	Potential role of metabolomics in the improvement of research on traditional African medicine. <i>Phytochemistry Letters</i> , 2016 , 17, 270-277	1.9	9
93	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. <i>Neurology</i> , 2016 , 87, 1329-36	6.5	255
92	Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. <i>Neurology</i> , 2016 , 87, 2050-2057	6.5	43
91	Multimodal Image Analysis in Alzheimer's Disease via Statistical Modelling of Non-local Intensity Correlations. <i>Scientific Reports</i> , 2016 , 6, 22161	4.9	14
90	A novel use of arterial spin labelling MRI to demonstrate focal hypoperfusion in individuals with posterior cortical atrophy: a multimodal imaging study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1032-4	5.5	8
89	Academic dishonesty in higher education: students' perceptions and involvement in an African institution. <i>BMC Research Notes</i> , 2016 , 9, 234	2.3	9
88	Functional neuroanatomy of spatial sound processing in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016 , 39, 154-64	5.6	20
87	Effect of age at onset on cortical thickness and cognition in posterior cortical atrophy. <i>Neurobiology of Aging</i> , 2016 , 44, 108-113	5.6	6
86	Neuroscience-related research in Ghana: a systematic evaluation of direction and capacity. <i>Metabolic Brain Disease</i> , 2016 , 31, 11-24	3.9	6
85	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016 , 86, 829-35	6.5	135
84	Disregard of neurological impairments associated with neglected tropical diseases in Africa. <i>ENeurologicalSci</i> , 2016 , 3, 11-14	2.1	10

(2016-2016)

83	The habenula: an under-recognised area of importance in frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 910-2	5.5	10
82	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. <i>Brain</i> , 2016 , 139, 1211-25	11.2	135
81	Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. <i>Alzheimerh and Dementia</i> , 2016 , 12, 1116-1124	1.2	139
80	Inflammatory changes in very early Alzheimer's disease: friend, foe, or don't know?. <i>Brain</i> , 2016 , 139, 647-50	11.2	3
79	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016 , 87, 1000-4	5.5	50
78	Altered sense of humor in dementia. <i>Journal of Alzheimerl</i> Disease, 2016 , 49, 111-9	4.3	27
77	Evaluation of Changes in Ghanaian Students' Attitudes Towards Science Following Neuroscience Outreach Activities: A Means to Identify Effective Ways to Inspire Interest in Science Careers. Journal of Undergraduate Neuroscience Education: JUNE: A Publication of FUN, Faculty for	0.6	5
76	Developing Science Communication in Africa: Undergraduate and Graduate Students should be Trained and Actively Involved in Outreach Activity Development and Implementation. <i>Journal of</i> Undergraduate Neuroscience Education: JUNE: A Publication of FUN, Faculty for Undergraduate	0.6	3
75	A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	2
74	Build the Future of Science Communication in Developing Countries through Systematic Training of Young Scientists. <i>Journal of Microbiology and Biology Education</i> , 2016 , 17, 327-328	1.3	1
73	Social Factors Influencing Child Health in Ghana. <i>PLoS ONE</i> , 2016 , 11, e0145401	3.7	24
72	Assessment of the quality of groundwater for drinking purposes in the Upper West and Northern regions of Ghana. <i>SpringerPlus</i> , 2016 , 5, 2001		17
71	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. <i>Journal of Alzheimerls Disease</i> , 2016 , 54, 1297-1302	4.3	20
70	The palmomental reflex: stop scratching around!. <i>Practical Neurology</i> , 2016 , 16, 500-501	2.4	4
69	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimerl</i> s and Dementia, 2016 , 12, 862-71	1.2	64
68	Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy. <i>Clinical Neurology and Neurosurgery</i> , 2016 , 144, 64-6	2	
67	A physiological signature of sound meaning in dementia. <i>Cortex</i> , 2016 , 77, 13-23	3.8	17
66	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. <i>Neurobiology of Aging</i> , 2016 , 39, 99-107	5.6	18

65	Humour processing in frontotemporal lobar degeneration: A behavioural and neuroanatomical analysis. <i>Cortex</i> , 2015 , 69, 47-59	3.8	34
64	White matter tract signatures of impaired social cognition in frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2015 , 8, 640-51	5.3	54
63	Identification of environmental sounds and melodies in syndromes of anterior temporal lobe degeneration. <i>Journal of the Neurological Sciences</i> , 2015 , 352, 94-8	3.2	19
62	Functional neuroanatomy of auditory scene analysis in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015 , 7, 699-708	5.3	28
61	Cerebrospinal fluid tau and amyloid-II-42 in patients with dementia. <i>Brain</i> , 2015 , 138, 2716-31	11.2	105
60	Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy. <i>Brain</i> , 2015 , 138, 1976-91	11.2	53
59	New criteria for Alzheimer's disease: which, when and why?. Brain, 2015, 138, 1134-7	11.2	9
58	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 1225-33	5.5	84
57	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. <i>Journal of Neurology</i> , 2015 , 262, 2722-30	5.5	34
56	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 3140-3151	5.6	46
55	Physiological phenotyping of dementias using emotional sounds. <i>Alzheimerh</i> and <i>Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 170-178	5.2	18
54	A simulation system for biomarker evolution in neurodegenerative disease. <i>Medical Image Analysis</i> , 2015 , 26, 47-56	15.4	8
53	Picturing the torment of cluster headache. <i>Neurology</i> , 2015 , 85, 1430-1	6.5	
52	Pain and temperature processing in dementia: a clinical and neuroanatomical analysis. <i>Brain</i> , 2015 , 138, 3360-72	11.2	74
51	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. <i>NeuroImage</i> , 2015 , 123, 149-64	7.9	48
50	Auditory hedonic phenotypes in dementia: A behavioural and neuroanatomical analysis. <i>Cortex</i> , 2015 , 67, 95-105	3.8	35
49	P4-189: Effect of brain-specific kinase-dependent tau phosphorylation on tauopathy-associated sundowning sleep behaviour 2015 , 11, P852-P852		
48	Differential hippocampal shapes in posterior cortical atrophy patients: A comparison with control and typical AD subjects. <i>Human Brain Mapping</i> , 2015 , 36, 5123-36	5.9	16

(2014-2015)

47	Do cerebrospinal fluid transfer methods affect measured amyloid \$\mathbb{Q}2\$, total tau, and phosphorylated tau in clinical practice?. <i>Alzheimerl</i> s and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015 , 1, 380-4	5.2	4
46	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. <i>Alzheimerl</i> s and Dementia: Diagnosis, Assessment and Disease Monitoring , 2015 , 1, 440-446	5.2	13
45	Letter to the editor. Journal of Microbiology and Biology Education, 2015, 16, 3-4	1.3	9
44	Dementias show differential physiological responses to salient sounds. <i>Frontiers in Behavioral Neuroscience</i> , 2015 , 9, 73	3.5	21
43	Motor Neuron Diseases in Sub-Saharan Africa: The Need for More Population-Based Studies. <i>BioMed Research International</i> , 2015 , 2015, 298409	3	20
42	Auditory spatial processing in Alzheimer's disease. <i>Brain</i> , 2015 , 138, 189-202	11.2	35
41	Developing expertise in bioinformatics for biomedical research in Africa. <i>Applied & Translational Genomics</i> , 2015 , 6, 31-34		24
40	Neurogenomics: An opportunity to integrate neuroscience, genomics and bioinformatics research in Africa. <i>Applied & Translational Genomics</i> , 2015 , 5, 3-10		19
39	Widening participation would be key in enhancing bioinformatics and genomics research in Africa. <i>Applied & Translational Genomics</i> , 2015 , 6, 35-41		3
38	Neurogenomics: Challenges and opportunities for Ghana. <i>Applied & Translational Genomics</i> , 2015 , 5, 11-	-14	4
37	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <i>Molecular Neurodegeneration</i> , 2015 , 10, 64	19	87
36	Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 708-13	5.5	81
35	Bioinformatics in Africa: The Rise of Ghana?. PLoS Computational Biology, 2015, 11, e1004308	5	36
34	Bridging the gap: Introducing neuroscience to Ghana. <i>Biochemist</i> , 2015 , 37, 46-47	0.5	6
33	R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. <i>Alzheimerh</i> and <i>Dementia</i> , 2014 , 10, 602-608.e4	1.2	74
32	P1-020: AUDITORY SPATIAL PROCESSING IN ALZHEIMER'S DISEASE AND POSTERIOR CORTICAL ATROPHY 2014 , 10, P311-P311		
31	IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS 2014 , 10, P32-P33		
30	P1-286: STRATIFICATION OF DEMENTIA SUB-TYPES USING ARTERIAL SPIN LABELED MRI 2014 , 10, P41-	4-P415	i 1

29	O2-05-01: A DATA-DRIVEN MODEL OF BIOMARKER CHANGES IN SPORADIC ALZHEIMER'S DISEASE 2014 , 10, P172-P172		3
28	P1-346: IDENTIFICATION OF ENVIRONMENTAL SOUNDS AND MELODIES IN SYNDROMES OF ANTERIOR TEMPORAL LOBE DEGENERATION 2014 , 10, P440-P440		
27	O2-14-06: ABNORMALITIES OF FIXATION, SACCADE, AND PURSUIT IN POSTERIOR CORTICAL ATROPHY COMPARED TO TYPICAL AD 2014 , 10, P199-P199		1
26	P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS 2014 , 10, P540-P541		
25	Altered body schema processing in frontotemporal dementia with C9ORF72 mutations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1016-23	5.5	24
24	Prominent effects and neural correlates of visual crowding in a neurodegenerative disease population. <i>Brain</i> , 2014 , 137, 3284-99	11.2	25
23	Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study. <i>JAMA Neurology</i> , 2014 , 71, 421-8	17.2	43
22	A data-driven model of biomarker changes in sporadic Alzheimer's disease. <i>Brain</i> , 2014 , 137, 2564-77	11.2	149
21	Amyloid-beta 42 adsorption following serial tube transfer. <i>Alzheimerl</i> s <i>Research and Therapy</i> , 2014 , 6, 5	9	31
20	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014 , 83, 1945-53	6.5	186
19	Inflammation in Alzheimer's disease: insights from immunotherapy. <i>Brain</i> , 2013 , 136, 2654-6	11.2	33
18	Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations. <i>Journal of Alzheimerl</i> s <i>Disease</i> , 2013 , 35, 199-212	4.3	31
17	Posterior cortical atrophy. <i>Lancet Neurology, The</i> , 2012 , 11, 170-8	24.1	383
16	Using CSF biomarkers to replicate genetic associations in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012 , 33, 1486.e9-15	5.6	20
15	Alzheimer's disease: mimics and chameleons. <i>Practical Neurology</i> , 2012 , 12, 358-66	2.4	16
14	Algorithms, atrophy and Alzheimer's disease: cautionary tales for clinical trials. <i>NeuroImage</i> , 2011 , 57, 15-18	7.9	64
13	Combining biomarkers: the future for Alzheimer disease prevention studies?. <i>Neurodegenerative Disease Management</i> , 2011 , 1, 175-178	2.8	
12	Suspected early dementia. <i>BMJ, The</i> , 2011 , 343, d5568	5.9	2

LIST OF PUBLICATIONS

11	multiple time point study. <i>Brain</i> , 2010 , 133, 3315-22	11.2	45
10	Brain biopsy in dementia: clinical indications and diagnostic approach. <i>Acta Neuropathologica</i> , 2010 , 120, 327-41	14.3	49
9	Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid All-42. <i>Annals of Neurology</i> , 2010 , 68, 825-34	9.4	123
8	New developments in mild cognitive impairment and Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2006 , 19, 552-8	7.1	17
7	Delineating the sites and progression of in vivo atrophy in multiple system atrophy using fluid-registered MRI. <i>Movement Disorders</i> , 2003 , 18, 955-8	7	19
6	Assessing the onset of structural change in familial Alzheimer's disease. <i>Annals of Neurology</i> , 2003 , 53, 181-8	9.4	140
5	Diagnostic value of plasma neurofilament light: A multicentre validation study		6
4	Time course of phosphorylated tau181 in blood across the Alzheimer∄ disease spectrum		2
3	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer Disease Neuroimaging Initiative		1
2	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer disease		2
1	Biomarker modeling of Alzheimer disease using PET-based Braak staging. <i>Nature Aging</i> ,		2